<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406781</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2014-04</org_study_id>
    <secondary_id>2014-004568-39</secondary_id>
    <nct_id>NCT02406781</nct_id>
  </id_info>
  <brief_title>Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial</brief_title>
  <acronym>PEMBROSARC</acronym>
  <official_title>Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immune Design</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study assessing the efficacy of different therapeutic strategy in&#xD;
      patients with advanced sarcomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 trial with 7 strata :&#xD;
&#xD;
        -  Leiomyosarcoma (strata 1) : 33 patients&#xD;
&#xD;
        -  Undifferentiated sarcoma (strata 2): 33 patients&#xD;
&#xD;
        -  Sarcomas others (strata 3) : 33 patients&#xD;
&#xD;
        -  Osteosarcoma (strata 4) : 33 patients&#xD;
&#xD;
        -  GIST (strata 5): 31 patients&#xD;
&#xD;
        -  Advanced soft-tissue sarcoma with immune signature (strata 6): 32 patients&#xD;
&#xD;
        -  Metastatic soft-tissue sarcoma (strata 7): 32 patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">November 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide per RECIST v1.1 criteria</measure>
    <time_frame>6 months</time_frame>
    <description>This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) independently for 6 strata as per RECIST v1.1 criteria :&#xD;
In terms of 6-month objective response and 6-months non progression for:&#xD;
Advanced leiomyosarcoma&#xD;
Advanced undifferentiated sarcoma&#xD;
Advanced other sarcoma&#xD;
Advanced osteosarcoma&#xD;
In terms of·6-month non progression for:&#xD;
Advanced GIST&#xD;
Advanced soft-tissue sarcoma with immune signature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the efficacy of MK3475 associated with Metronomic Cyclophosphamide and G100 per RECIST v1.1 criteria</measure>
    <time_frame>6 months</time_frame>
    <description>This primary objective of this study is to assess the efficacy of MK3475 and Metronomic Cyclophosphamide (CP) and G100 as per RECIST v1.1 criteria, in terms of 6-months non progression for metastatic soft-tissue sarcoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Best overall response</measure>
    <time_frame>participants will be followed for the duration of treatment, an expected average of 6-months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of best overall response (as per RECIST v1.1 criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Progression-free Survival</measure>
    <time_frame>Progression-free survival assessed at 12 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 1-year progression-free survival (as per RECIST v1.1 criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Immune_related Response</measure>
    <time_frame>Immune-related response assessed at 6 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 6-months immune-related response (as per Wolchok 2009)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment strategy in terms of Overall Survival.</measure>
    <time_frame>Overall survival assessed at 12 months</time_frame>
    <description>Assessment of the efficacy of the treatment strategy in terms of 1-year overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of the treatment strategy.Toxicity graded using the Common Terminology Criteria for Adverse Events version 4</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
    <description>Toxicity graded using the Common Terminology Criteria for Adverse Events version 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of blood cytokines levels (TNFγ, TNFα, TGFβ, IL2, 4, 6, 10) (ELISA)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of blood VEGF, Svegfr2 and TPS-1 levels (ELISA)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of lymphocytes subpopulations monitoring, CD8+/Treg ratio (flow cytometry)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploration of Plasma levels of Kynurenine and Kynurenine to Tryptophan ratio (ELISA and LC/MS)</measure>
    <time_frame>Blood samples collected at different time points : Baseline, Day 8 cycle 1, Day 8 cycle 2, Day 8 cycle 3, Day 8 cycle 4, Day 8 Cycle 6 and at progression</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment strategy A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment strategy B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of MK3475 with Metronomic CP</intervention_name>
    <description>Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.&#xD;
MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.</description>
    <arm_group_label>Treatment strategy A</arm_group_label>
    <other_name>Pembrolizumab, Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of MK3475 with Metronomic CP and G100</intervention_name>
    <description>Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.&#xD;
MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.&#xD;
G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).&#xD;
A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.</description>
    <arm_group_label>Treatment strategy B</arm_group_label>
    <other_name>Pembrolizumab, Endoxan, GLA-SE (glucopyranosyl lipid adjuvant-stable emulsion).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histology : Leiomyosarcoma, or UPS, or other sarcoma, or GIST or osteosarcoma, or&#xD;
             soft-tissue sarcoma with presence of tertiary lymphoid structures (stratum 6)&#xD;
             histologically confirmed by central review.&#xD;
&#xD;
          2. Advanced non resectable / metastatic disease for strata 1 to 6. For stratum 7: locally&#xD;
             advanced or metastatic disease with at least one injectable lesion.&#xD;
&#xD;
          3. Documented progression according to RECIST criteria. Progression on the last line of&#xD;
             treatment should be confirmed by central review with two radiological assessments&#xD;
             identical obtained at less than 6 months interval within the 12 months before&#xD;
             inclusion.&#xD;
&#xD;
          4. For stratum 5, documented disease progression according to RECIST criteria after the&#xD;
             first line imatinib and second line sunitinib.&#xD;
&#xD;
          5. Have provided tissue of a tumor lesion from an archival tissue sample obtained on&#xD;
             metastasis or on locally advanced disease, or newly obtained core or excisional&#xD;
             biopsy. For strata 6 and 7, tissue &lt; 3 months old and with no subsequent treatment&#xD;
             since or from a newly obtained biopsy.&#xD;
&#xD;
          6. For strata 1, 2, 3 and 6: no more of four previous lines of systemic therapy for&#xD;
             metastatic disease and no more than 2 previous line for stratum 7.&#xD;
&#xD;
          7. Age ≥ 18 years.&#xD;
&#xD;
          8. ECOG performance status ≤ 1.&#xD;
&#xD;
          9. Measurable disease according to RECIST v1.1 outside any previously irradiated field.&#xD;
             At least one site of disease must be uni-dimensionally ≥ 10 mm.&#xD;
&#xD;
         10. Life expectancy &gt; 3 months (except for stratum 7 &gt; 6 months).&#xD;
&#xD;
         11. ≥ 1 previous line (s) of chemotherapy in the palliative setting for strata 1 to 5. For&#xD;
             other strata, participant must have advanced disease and must not be a candidate for&#xD;
             other approved therapeutic regimen known to provide significant clinical benefit based&#xD;
             on investigator judgement.&#xD;
&#xD;
         12. No symptomatic central nervous system disease.&#xD;
&#xD;
         13. No chronic use of glucocorticoids.&#xD;
&#xD;
         14. Adequate hematological, renal, metabolic and hepatic function:&#xD;
&#xD;
               1. Hemoglobin ≥ 9 g/dl (patients may have received prior red blood cell&#xD;
                  transfusion); ANC ≥ 1.5 x 109/l and platelet count ≥ 100 x 109/l. For stratum 7:&#xD;
                  lymphocyte count ≥ 0.5.109 /l&#xD;
&#xD;
               2. ALT and AST ≤ 2.5 x upper limit of normality (ULN) (≤ 5 in case of liver&#xD;
                  metastasis)&#xD;
&#xD;
               3. Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total&#xD;
                  bilirubin levels ≥ 1.5 x ULN&#xD;
&#xD;
               4. Albumin ≥ 25g/l&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN OR CrCl ≥ 60 ml/min for subject with creatinine&#xD;
                  levels ≥ 1.5 x ULN,&#xD;
&#xD;
               6. Creatine phosphokinase ≤ 2.5 x ULN&#xD;
&#xD;
               7. INR ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT&#xD;
                  or PTT is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
               8. aPTT ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT&#xD;
                  or PTT is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
         15. No prior or concurrent malignant disease diagnosed or treated in the last 2 years&#xD;
             except for adequately treated in situ carcinoma of the cervix, basal or squamous skin&#xD;
             cell carcinoma, or in situ transitional bladder cell carcinoma.&#xD;
&#xD;
         16. At least three weeks since last chemotherapy, immunotherapy or any other&#xD;
             pharmacological treatment and/or radiotherapy.&#xD;
&#xD;
         17. Recovery to grade ≤ 1 from any adverse event from previous treatment (excluding&#xD;
             alopecia of any grade and non-painful peripheral neuropathy grade ≤ 2 (NCI-CTCAE, v&#xD;
             4.0).&#xD;
&#xD;
         18. Women of childbearing potential must have a negative serum pregnancy test within 72&#xD;
             hours prior to receiving the first dose of study medication. Both women and men must&#xD;
             agree to use a medically acceptable method of contraception throughout the treatment&#xD;
             period and for four months after discontinuation of treatment. Acceptable methods for&#xD;
             contraception include intrauterine device, oral contraceptive, subdermal implant and&#xD;
             double barrier. Subjects of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for ≥ 1 year.&#xD;
&#xD;
         19. Voluntary signed and dated written informed consents prior to any specific study&#xD;
             procedure.&#xD;
&#xD;
         20. Patients with a French social security in compliance with the Law relating to&#xD;
             biomedical research (Article 1121-11 of French Public Health Code).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with MK3475 or CP or G100.&#xD;
&#xD;
          2. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or&#xD;
             anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically&#xD;
             targeting T-cell co-stimulation or checkpoint pathways).&#xD;
&#xD;
          3. Evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal&#xD;
             metastases.&#xD;
&#xD;
          4. Men or women of childbearing potential who are not using an effective method of&#xD;
             contraception as previously described; women who are pregnant or breast feeding.&#xD;
&#xD;
          5. Participation to a study involving a medical or therapeutic intervention in the last&#xD;
             30 days.&#xD;
&#xD;
          6. Previous enrolment in the present study.&#xD;
&#xD;
          7. Patient unable to follow and comply with the study procedures because of any&#xD;
             geographical, familial, social or psychological reasons.&#xD;
&#xD;
          8. Known hypersensitivity to any involved study drug or of its formulation components.&#xD;
&#xD;
          9. Has an active autoimmune disease requiring systemic treatment within the past 3 months&#xD;
             or a documented history of clinically severe autoimmune disease, or a syndrome that&#xD;
             requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or&#xD;
             resolved childhood asthma/atopy would be an exception to this rule. Subjects that&#xD;
             require intermittent use of bronchodilators or local steroid injections would not be&#xD;
             excluded from the study. Subjects with hypothyroidism stable on hormone replacement or&#xD;
             Sjorgen's syndrome will not be excluded from the study.&#xD;
&#xD;
         10. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
         11. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced&#xD;
             pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening&#xD;
             chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is&#xD;
             permitted.&#xD;
&#xD;
         12. Has known active hepatitis B or hepatitis C.&#xD;
&#xD;
         13. Has a known history of HIV (HIV1/2 antibodies).&#xD;
&#xD;
         14. Has received a live vaccine within 30 days prior to the first dose of trial treatment.&#xD;
&#xD;
         15. For strata 6 to 7:&#xD;
&#xD;
               -  patients with oral anticoagulation therapy&#xD;
&#xD;
               -  known urinary tract obstruction&#xD;
&#xD;
               -  previous allogenic bone marrow transplant&#xD;
&#xD;
               -  has an active infection requiring systemic treatment within 14 days prior to&#xD;
                  study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy of MK 3475 with Metronomic Cyclophosphamide</keyword>
  <keyword>Advanced Sarcomas</keyword>
  <keyword>Leiomyosarcoma</keyword>
  <keyword>Undifferentiated Sarcoma</keyword>
  <keyword>Other Sarcoma</keyword>
  <keyword>GIST</keyword>
  <keyword>Osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

